Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
Objectives: Long-term nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral treatment failure in most developing countries has led to broad cross-resistance within NNRTI and nucleoside reverse transcriptase inhibitor (NRTI) classes. In this study, we investigated the efficacy an...
Saved in:
Main Authors: | P. Chetchotisakd, S. Anunnatsiri, P. Mootsikapun, S. Kiertiburanakul, T. Anekthananon, C. Bowonwatanuwong, B. Kowadisaiburana, K. Supparatpinyo, K. Ruxrungtham |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35448967037&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61246 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
by: P. Chetchotisakd, et al.
Published: (2018) -
High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant
by: Ploenchan Chetchotisakd, et al.
Published: (2018) -
High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant
by: Ploenchan Chetchotisakd, et al.
Published: (2018) -
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study
by: Torsak Bunupuradah, et al.
Published: (2018) -
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir
by: Weerawat Manosuthi, et al.
Published: (2018)